Ozempic Must Be Discontinued Immediately in This 6-Week Pregnancy
No, Ozempic (semaglutide) cannot be used during pregnancy and should be stopped immediately now that pregnancy has been confirmed at 6 weeks 2 days. The most recent 2025 Endocrine Society/European Society of Endocrinology joint clinical practice guideline explicitly states that "GLP-1RA use is not recommended during pregnancy" 1. The FDA drug label for Ozempic confirms this, stating it "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" based on animal studies showing embryofetal mortality, structural abnormalities, and early pregnancy losses 2.
Immediate Action Required
Stop Ozempic now and transition to insulin with active glucose monitoring. The guideline emphasizes that "effective coordination of care in both the preconception period and early pregnancy is needed with discontinuation of GLP-1RAs, and glucose should be immediately and actively monitored" 1.
Critical Management Steps:
- Discontinue semaglutide immediately - do not wait for the next scheduled dose
- Start insulin therapy promptly - insulin is the preferred antidiabetic medication in pregnancy 3
- Monitor glucose intensively - sudden discontinuation can cause rebound hyperglycemia, which increases risk for congenital malformations and spontaneous abortion 1
- Consider adding metformin if needed for glycemic control, though insulin remains first-line 3
Why Discontinuation Is Critical at 6 Weeks
At 6 weeks 2 days, the patient is in the critical period of organogenesis (weeks 3-8 of gestation). The guideline notes that "GLP-1 receptors are expressed in the human placenta; therefore, although available data shows minimal placental transfer, the impact of GLP-1RAs on the GLP-1 receptors in the placenta are unknown" 1. Animal studies showed structural abnormalities affecting the heart, blood vessels, cranial bones, vertebrae, and ribs at clinically relevant exposures 2.
Reassurance About First Trimester Exposure
However, inadvertent first-trimester exposure does not automatically predict poor outcomes. Recent 2026 research provides some reassurance:
- A systematic review of 1,128 semaglutide-exposed pregnancies found "no clear association with birth defects" and "no consistent increased risk of major congenital malformations" 4
- Multiple case series reported normal pregnancy outcomes following first-trimester exposure 5, 6, 7
- One observational study found "no difference in congenital anomalies, spontaneous abortions, or increased numbers of LGA or SGA neonates" compared to reference groups 1
The guideline acknowledges that "the only comparative study identified was indirect evidence restricted to pregnancies resulting from live births and exposure to GLP-1RAs based on filled prescription history. A minority of the study population had preexisting T2DM and had GLP-1RA exposure, which was discontinued in early pregnancy" 1.
Key Pitfalls to Avoid
Do not delay insulin initiation while waiting for glucose to rise. The guideline warns that "sudden discontinuation of GLP-1RA may cause hyperglycemia and weight gain, which increases the risk for congenital malformations and spontaneous abortion. Timely transition and titration of alternative antihyperglycemic agents after discontinuing GLP-1RAs is necessary to minimize hyperglycemia" 1.
Do not use glyburide as an alternative - it crosses the placenta and is associated with increased neonatal hypoglycemia and macrosomia 3.
Monitor for excessive gestational weight gain - one study noted that "excess gestational weight gain has been observed in those exposed to GLP-1RAs before pregnancy compared with those who were not" 1.
Ongoing Monitoring Plan
- Detailed anatomic ultrasound at 18-20 weeks to assess for structural abnormalities, particularly cardiac and skeletal
- Serial growth ultrasounds to monitor for macrosomia or growth restriction
- Tight glycemic control with target glucose 63-140 mg/dL, time in range >70% 3
- Screen for preeclampsia - one case series noted an 18.8% rate 7
The manufacturer recommends discontinuing Ozempic "at least 2 months before a planned pregnancy due to the long washout period for semaglutide" 2, but since this pregnancy is already established, immediate discontinuation with aggressive glucose management is the priority.